Michael L. Grossbard, MD

Articles

Dr. Grossbard on the Role of Maintenance Rituximab in Follicular Lymphoma

May 21st 2020

Michael L. Grossbard, MD, discusses the role of maintenance rituximab (Rituxan) in follicular lymphoma.

Dr. Grossbard on the Role of Maintenance Rituximab in Follicular Lymphoma

May 20th 2020

Michael L. Grossbard, MD, discusses the role of maintenance rituximab (Rituxan) in follicular lymphoma.

Dr. Grossbard on the Activity of Venetoclax in Follicular Lymphoma

April 24th 2020

Michael L. Grossbard, MD, discusses the activity of venetoclax in follicular lymphoma.

Dr. Grossbard on the DYNAMO Study With Duvelisib in Follicular Lymphoma

April 17th 2020

Michael L. Grossbard, MD, discusses the phase III DYNAMO study examining the use of duvelisib in the treatment of patients with indolent non-Hodgkin lymphoma.

Dr. Grossbard on the Role of MRD in Follicular Lymphoma

March 24th 2020

Michael L. Grossbard, MD, discusses the role of minimal residual disease in follicular lymphoma.

Dr. Grossbard on the GALLIUM Study in Follicular Lymphoma

March 17th 2020

Michael L. Grossbard, MD, professor in the Department of Medicine, chief of the Hematology and Medical Oncology Inpatient Service at Tisch Hospital, and section chief of Hematology at NYU Langone Health’s Perlmutter Cancer Center, discusses the results of the phase III GALLIUM study in follicular lymphoma.

Dr. Grossbard on the Utility of PI3K Inhibitors in Follicular Lymphoma

March 5th 2020

Michael L. Grossbard, MD, discusses the utility of PI3K inhibitors in follicular lymphoma.

x